Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 6Phase 1/2 3Phase 3 2Phase NA 1Phase 4 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Upper Tract Urothelial Carcinomas 1Breast Neoplasms 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Drug Evaluation × Clear all
NCT05054751 2024-10-10

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Genor Biopharma Co., Ltd.

Phase 3 Completed
275 enrolled
Breast

Breast Neoplasms

NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated
39 enrolled 31 charts
Genitourinary

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡